)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cynata Therapeutics
Cynata Therapeutics (CYP) investor relations material
Cynata Therapeutics Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary26 Oct, 2026
Executive summary
Cost reductions reshaped operations: all employee positions were made redundant, service-provider work was curtailed, and the Board is assessing development pathways and strategic options for the Cymerus platform.
Financial highlights
Quarter-end cash was $175k; net operating cash outflow was $1.316m, including $334k for R&D, $823k for staff costs and $143k for administration and corporate costs.
Related-party payments of $273k comprised salary and termination payments to the former Managing Director.
Subsequent to quarter end, a $1.694m FY2026 R&D tax refund was received; after repaying the loan, net proceeds were $1.067m.
Outlook and guidance
Following the cost cuts and expected entitlement-offer proceeds, cash runway is expected to extend into FY2028.
Board priorities include evaluating future development pathways for Cymerus, seeking to realise value from the technology and considering rights to new assets.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cynata Therapeutics
- Clinical trial failures drove restructuring, deep losses, and a shift to Board-led management.CYP
H2 2026 - Both major trials failed efficacy endpoints but confirmed safety, prompting a strategic review.CYPStudy update
- Advancing clinical pipeline and scalable MSC technology set up multiple near-term catalysts.CYPAGM 2024 presentation
- CYP-006TK showed strong safety and efficacy in DFU, with robust financial support secured.CYPStudy update
- Strong DFU results and cash position support major clinical milestones into 2026.CYPQ2 2025 TU
- Major clinical milestones and robust cash position support continued development into 2026.CYPQ3 2025 TU
- Three major clinical trial readouts and strong cash runway expected by mid-2026.CYPQ4 2025 TU
- Pivotal clinical results and strong cash runway set stage for major commercial opportunities.CYPQ1 2026 TU
- Pivotal clinical trial results in Q2 CY 2026 could transform commercial prospects.CYPQ2 2026 TU
Next Cynata Therapeutics earnings date
H1 202725 Feb, 2027
Cynata Therapeutics
Next Cynata Therapeutics earnings date
H1 202725 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)